Yields continue to rattle investors. These sectors are most at risk if rates stay elevated

The 10-year Treasury yield has risen more than 90 bps in 2026 to above 5.3% earlier this month, while September CPI rose 3.7% year over year, above expectations and prompting traders to price in at least one more Fed hike before year-end. Higher rates pose risks to homebuilders, utilities, technology and small caps: the home-construction ETF fell 7.3% in September, utilities dropped more than 6%, and the Russell 2000 is down over 11% from its August record. Healthcare is viewed as more resilient given steady earnings and demand; Abbott has 65% buy ratings and an average target implying nearly 16% upside from Thursday's close.

Analysis

The key risk is not simply another Fed hike: a persistent rise in long-end yields would tighten financing conditions even without further policy action. That keeps pressure on housing affordability and on capital-intensive businesses, while raising the discount rate for long-duration equities. For AI infrastructure, the market may increasingly distinguish companies with financing-dependent buildouts from chip suppliers whose economics are less directly tied to project funding; CoreWeave is an exposed watch item, but debt maturities, cash generation and funding terms are needed to quantify risk. Conversely, rate volatility could support CME Group if it translates into higher trading activity—verify volumes before treating that as an earnings catalyst.

Healthcare’s steadier demand may cushion earnings, but it is not immune to multiple compression. The named stocks are not interchangeable: assess company-specific guidance and valuation rather than buying the sector on a defensive label. In the next 1–3 months, inflation releases, long-end yield moves and company guidance are the main catalysts. Over 6–18 months, refinancing costs and delayed capital spending could widen performance gaps. The contrarian risk: if yields retreat, crowded defensives may lag a sharp recovery in rate-sensitive cyclicals; if yields stay high, the market may be underpricing funding risk in leveraged growth and smaller companies.

Key Decisions for Investors

• Consider a small relative-value position: short ITB versus long a diversified healthcare proxy such as XLV, adding only if long yields resume rising and housing-demand indicators weaken. Falsify on a sustained yield retreat or improving builder demand/pricing; keep the healthcare leg sized for valuation risk.
• Treat CoreWeave as a financing-risk watch, not an automatic short. Before positioning, verify debt maturities, interest costs, liquidity, committed customer funding and capex obligations; worsening funding terms or a guidance cut would strengthen the downside case.
• Monitor CME Group trading-volume disclosures as a potential volatility beneficiary. Do not assume higher yields alone lift earnings; the thesis weakens if rate volatility fades without increased activity.
• For ABT, BSX and CVS, require company-level evidence—earnings guidance, margins and valuation support—before using them as defensive longs. Analyst targets cited in the article are not a catalyst or a margin of safety.